In conclusion, this study changes the concept of RDEB physiopathology by demonstrating that it is a systemic, chronic inflammatory fibrotic disease, and by describing evidence-based efficacy of losartan treatment on events related to TGF-β-mediated dysregulation of inflammation and ECM remodeling. This evidence concerns the gene TGFB1 and recessive dystrophic epidermolysis bullosa.